Your browser doesn't support javascript.
loading
Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development.
Azizian-Farsani, Fatemeh; Abedpoor, Navid; Hasan Sheikhha, Mohammad; Gure, Ali Osmay; Nasr-Esfahani, Mohammad Hossein; Ghaedi, Kamran.
Afiliação
  • Azizian-Farsani F; Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Abedpoor N; Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, Academic Center for Education, Culture and Reasearch (ACECR), Isfahan, Iran.
  • Hasan Sheikhha M; Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Gure AO; Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Turkey.
  • Nasr-Esfahani MH; Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, Academic Center for Education, Culture and Reasearch (ACECR), Isfahan, Iran.
  • Ghaedi K; Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, Academic Center for Education, Culture and Reasearch (ACECR), Isfahan, Iran.
Front Oncol ; 10: 552283, 2020.
Article em En | MEDLINE | ID: mdl-33117687
ABSTRACT
Receptor for advanced glycation end-products (RAGE) is a multiligand binding and single-pass transmembrane protein taken in diverse chronic inflammatory conditions. RAGE behaves as a pattern recognition receptor, which binds and is engaged in the cellular response to a variety of damage-associated molecular pattern molecules, as well as HMGB1, S100 proteins, and AGEs (advanced glycation end-products). The RAGE activation turns out to a formation of numerous intracellular signaling mechanisms, resulting in the progression and prolongation of colorectal carcinoma (CRC). The RAGE expression correlates well with the survival of colon cancer cells. RAGE is involved in the tumorigenesis, which increases and develops well in the stressed tumor microenvironment. In this review, we summarized downstream signaling cascade activated by the multiligand activation of RAGE, as well as RAGE ligands and their sources, clinical studies, and tumor markers related to RAGE particularly in the inflammatory tumor microenvironment in CRC. Furthermore, the role of RAGE signaling pathway in CRC patients with diabetic mellitus is investigated. RAGE has been reported to drive assorted signaling pathways, including activator protein 1, nuclear factor-κB, signal transducer and activator of transcription 3, SMAD family member 4 (Smad4), mitogen-activated protein kinases, mammalian target of rapamycin, phosphoinositide 3-kinases, reticular activating system, Wnt/ß-catenin pathway, and Glycogen synthase kinase 3ß, and even microRNAs.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article